Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions
Purpose of Review Obesity is associated with cardiovascular (CV) conditions, including but not limited to atherosclerotic disease, heart failure, and atrial fibrillation. Despite this, the impact of intentional weight loss on CV outcomes for persons with obesity and established CV conditions remains...
Gespeichert in:
| Veröffentlicht in: | Current cardiology reports 2024-03, Vol.26 (3), p.61-71 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 71 |
|---|---|
| container_issue | 3 |
| container_start_page | 61 |
| container_title | Current cardiology reports |
| container_volume | 26 |
| creator | Harrington, Josephine Felker, G. Michael Januzzi, James L. Lam, Carolyn S. P. Lingvay, Ildiko Pagidipati, Neha J. Sattar, Naveed Van Spall, Harriette G. C. Verma, Subodh McGuire, Darren K. |
| description | Purpose of Review
Obesity is associated with cardiovascular (CV) conditions, including but not limited to atherosclerotic disease, heart failure, and atrial fibrillation. Despite this, the impact of intentional weight loss on CV outcomes for persons with obesity and established CV conditions remains poorly studied. New and emerging pharmacologic therapies for weight loss primarily targeting the incretin/nutrient sensing axes induce substantial and sustained weight loss. The glucagon-like-peptide 1 receptor agonists (GLP-1 RA) liraglutide and semaglutide have US FDA approval for the treatment of obesity, and the application for an obesity indication for the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide is presently under FDA review. Extensive phase II and IIIa randomized controlled trials are underway evaluating permutations of combined GLP-1 RA, GIP receptor agonist, GIP receptor antagonist, and glucagon receptor agonists. Clinical outcome trials of these therapies in persons with obesity at high risk of established CV conditions should make it possible to estimate the role of intentional weight loss in managing CV risk via these medications.
Recent Findings
High-dose once weekly injectable semaglutide (2.4 mg/week) use among persons with obesity and heart failure with preserved ejection fraction was effective at both reducing weight and improving health status; exercise capacity was also improved. Ongoing CV outcome trials of oral semaglutide and once weekly injectable tirzepatide will help to establish the role of these therapies among persons with other CV conditions. In addition to these two therapies targeting a CV claim or indication, many other new therapeutics for weight loss, as reviewed, are currently in development.
Summary
The impact of pharmacologic-induced weight loss on CV conditions for persons with obesity and established CV conditions is currently under investigation for multiple agents. These therapies may offer new avenues to manage CV risk in persons with obesity and with established or at high risk for CV disease. |
| doi_str_mv | 10.1007/s11886-023-02016-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3022573838</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3022573838</sourcerecordid><originalsourceid>FETCH-LOGICAL-c298t-63b176dc7110fcbdb75baa62ae64b12a3b4b770862ce525245045fbf1ba1e2cf3</originalsourceid><addsrcrecordid>eNp9kd9OHCEUxolpo3bbF-hFw2VvRvkzDOOV2WxsbWLqptF4SYA5M4uZgRXYGH0JX7m4o71sCIGc73c-cvgQ-krJCSVEniZK27apCONlE9pUzwfomApeV5xK8uH1XiQuW3aEPqV0TwpFZH2IjngrBJVtc4xe7kLMG3yzARfxHbhhk8_x0uPbbacz4ODxb3jE2nf4YoI4OD_g9UbHSdswhsFZvBzA54T7EPG1geTy056eDdchF9XpEf8JI-yhNcQUfMKPrjy70rFz2uJV8J3LrtQ_o4-9HhN8eTsX6PbHxc3qsrq6_vlrtbyqLDtrc9VwQ2XTWUkp6a3pjBRG64ZpaGpDmeamNlKStmEWBBOsFqQWvemp0RSY7fkCfZ99tzE87CBlNblkYRy1h7BLihPGhORtWQvEZtTGkFKEXm2jm3R8UpSo1yDUHIQqQah9EOq5NH1789-ZCbp_Le8_XwA-A6lIfoCo7sMu-jLz_2z_ArtMlag</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3022573838</pqid></control><display><type>article</type><title>Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Harrington, Josephine ; Felker, G. Michael ; Januzzi, James L. ; Lam, Carolyn S. P. ; Lingvay, Ildiko ; Pagidipati, Neha J. ; Sattar, Naveed ; Van Spall, Harriette G. C. ; Verma, Subodh ; McGuire, Darren K.</creator><creatorcontrib>Harrington, Josephine ; Felker, G. Michael ; Januzzi, James L. ; Lam, Carolyn S. P. ; Lingvay, Ildiko ; Pagidipati, Neha J. ; Sattar, Naveed ; Van Spall, Harriette G. C. ; Verma, Subodh ; McGuire, Darren K.</creatorcontrib><description>Purpose of Review
Obesity is associated with cardiovascular (CV) conditions, including but not limited to atherosclerotic disease, heart failure, and atrial fibrillation. Despite this, the impact of intentional weight loss on CV outcomes for persons with obesity and established CV conditions remains poorly studied. New and emerging pharmacologic therapies for weight loss primarily targeting the incretin/nutrient sensing axes induce substantial and sustained weight loss. The glucagon-like-peptide 1 receptor agonists (GLP-1 RA) liraglutide and semaglutide have US FDA approval for the treatment of obesity, and the application for an obesity indication for the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide is presently under FDA review. Extensive phase II and IIIa randomized controlled trials are underway evaluating permutations of combined GLP-1 RA, GIP receptor agonist, GIP receptor antagonist, and glucagon receptor agonists. Clinical outcome trials of these therapies in persons with obesity at high risk of established CV conditions should make it possible to estimate the role of intentional weight loss in managing CV risk via these medications.
Recent Findings
High-dose once weekly injectable semaglutide (2.4 mg/week) use among persons with obesity and heart failure with preserved ejection fraction was effective at both reducing weight and improving health status; exercise capacity was also improved. Ongoing CV outcome trials of oral semaglutide and once weekly injectable tirzepatide will help to establish the role of these therapies among persons with other CV conditions. In addition to these two therapies targeting a CV claim or indication, many other new therapeutics for weight loss, as reviewed, are currently in development.
Summary
The impact of pharmacologic-induced weight loss on CV conditions for persons with obesity and established CV conditions is currently under investigation for multiple agents. These therapies may offer new avenues to manage CV risk in persons with obesity and with established or at high risk for CV disease.</description><identifier>ISSN: 1523-3782</identifier><identifier>EISSN: 1534-3170</identifier><identifier>DOI: 10.1007/s11886-023-02016-z</identifier><identifier>PMID: 38551786</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Atrial Fibrillation ; Cardiology ; Cardiometabolic Disease (DM and CV) (CJ Lavie ; Diabetes Mellitus, Type 2 ; Glucagon-Like Peptide 1 ; Heart Diseases ; Heart Failure ; Humans ; Hypoglycemic Agents ; Medicine ; Medicine & Public Health ; Obesity - complications ; Obesity - drug therapy ; Section Editor ; Topical Collection on Cardiometabolic Disease (DM and CV) ; Weight Loss</subject><ispartof>Current cardiology reports, 2024-03, Vol.26 (3), p.61-71</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c298t-63b176dc7110fcbdb75baa62ae64b12a3b4b770862ce525245045fbf1ba1e2cf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11886-023-02016-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11886-023-02016-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38551786$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Harrington, Josephine</creatorcontrib><creatorcontrib>Felker, G. Michael</creatorcontrib><creatorcontrib>Januzzi, James L.</creatorcontrib><creatorcontrib>Lam, Carolyn S. P.</creatorcontrib><creatorcontrib>Lingvay, Ildiko</creatorcontrib><creatorcontrib>Pagidipati, Neha J.</creatorcontrib><creatorcontrib>Sattar, Naveed</creatorcontrib><creatorcontrib>Van Spall, Harriette G. C.</creatorcontrib><creatorcontrib>Verma, Subodh</creatorcontrib><creatorcontrib>McGuire, Darren K.</creatorcontrib><title>Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions</title><title>Current cardiology reports</title><addtitle>Curr Cardiol Rep</addtitle><addtitle>Curr Cardiol Rep</addtitle><description>Purpose of Review
Obesity is associated with cardiovascular (CV) conditions, including but not limited to atherosclerotic disease, heart failure, and atrial fibrillation. Despite this, the impact of intentional weight loss on CV outcomes for persons with obesity and established CV conditions remains poorly studied. New and emerging pharmacologic therapies for weight loss primarily targeting the incretin/nutrient sensing axes induce substantial and sustained weight loss. The glucagon-like-peptide 1 receptor agonists (GLP-1 RA) liraglutide and semaglutide have US FDA approval for the treatment of obesity, and the application for an obesity indication for the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide is presently under FDA review. Extensive phase II and IIIa randomized controlled trials are underway evaluating permutations of combined GLP-1 RA, GIP receptor agonist, GIP receptor antagonist, and glucagon receptor agonists. Clinical outcome trials of these therapies in persons with obesity at high risk of established CV conditions should make it possible to estimate the role of intentional weight loss in managing CV risk via these medications.
Recent Findings
High-dose once weekly injectable semaglutide (2.4 mg/week) use among persons with obesity and heart failure with preserved ejection fraction was effective at both reducing weight and improving health status; exercise capacity was also improved. Ongoing CV outcome trials of oral semaglutide and once weekly injectable tirzepatide will help to establish the role of these therapies among persons with other CV conditions. In addition to these two therapies targeting a CV claim or indication, many other new therapeutics for weight loss, as reviewed, are currently in development.
Summary
The impact of pharmacologic-induced weight loss on CV conditions for persons with obesity and established CV conditions is currently under investigation for multiple agents. These therapies may offer new avenues to manage CV risk in persons with obesity and with established or at high risk for CV disease.</description><subject>Atrial Fibrillation</subject><subject>Cardiology</subject><subject>Cardiometabolic Disease (DM and CV) (CJ Lavie</subject><subject>Diabetes Mellitus, Type 2</subject><subject>Glucagon-Like Peptide 1</subject><subject>Heart Diseases</subject><subject>Heart Failure</subject><subject>Humans</subject><subject>Hypoglycemic Agents</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Obesity - complications</subject><subject>Obesity - drug therapy</subject><subject>Section Editor</subject><subject>Topical Collection on Cardiometabolic Disease (DM and CV)</subject><subject>Weight Loss</subject><issn>1523-3782</issn><issn>1534-3170</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kd9OHCEUxolpo3bbF-hFw2VvRvkzDOOV2WxsbWLqptF4SYA5M4uZgRXYGH0JX7m4o71sCIGc73c-cvgQ-krJCSVEniZK27apCONlE9pUzwfomApeV5xK8uH1XiQuW3aEPqV0TwpFZH2IjngrBJVtc4xe7kLMG3yzARfxHbhhk8_x0uPbbacz4ODxb3jE2nf4YoI4OD_g9UbHSdswhsFZvBzA54T7EPG1geTy056eDdchF9XpEf8JI-yhNcQUfMKPrjy70rFz2uJV8J3LrtQ_o4-9HhN8eTsX6PbHxc3qsrq6_vlrtbyqLDtrc9VwQ2XTWUkp6a3pjBRG64ZpaGpDmeamNlKStmEWBBOsFqQWvemp0RSY7fkCfZ99tzE87CBlNblkYRy1h7BLihPGhORtWQvEZtTGkFKEXm2jm3R8UpSo1yDUHIQqQah9EOq5NH1789-ZCbp_Le8_XwA-A6lIfoCo7sMu-jLz_2z_ArtMlag</recordid><startdate>20240301</startdate><enddate>20240301</enddate><creator>Harrington, Josephine</creator><creator>Felker, G. Michael</creator><creator>Januzzi, James L.</creator><creator>Lam, Carolyn S. P.</creator><creator>Lingvay, Ildiko</creator><creator>Pagidipati, Neha J.</creator><creator>Sattar, Naveed</creator><creator>Van Spall, Harriette G. C.</creator><creator>Verma, Subodh</creator><creator>McGuire, Darren K.</creator><general>Springer US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240301</creationdate><title>Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions</title><author>Harrington, Josephine ; Felker, G. Michael ; Januzzi, James L. ; Lam, Carolyn S. P. ; Lingvay, Ildiko ; Pagidipati, Neha J. ; Sattar, Naveed ; Van Spall, Harriette G. C. ; Verma, Subodh ; McGuire, Darren K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c298t-63b176dc7110fcbdb75baa62ae64b12a3b4b770862ce525245045fbf1ba1e2cf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Atrial Fibrillation</topic><topic>Cardiology</topic><topic>Cardiometabolic Disease (DM and CV) (CJ Lavie</topic><topic>Diabetes Mellitus, Type 2</topic><topic>Glucagon-Like Peptide 1</topic><topic>Heart Diseases</topic><topic>Heart Failure</topic><topic>Humans</topic><topic>Hypoglycemic Agents</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Obesity - complications</topic><topic>Obesity - drug therapy</topic><topic>Section Editor</topic><topic>Topical Collection on Cardiometabolic Disease (DM and CV)</topic><topic>Weight Loss</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Harrington, Josephine</creatorcontrib><creatorcontrib>Felker, G. Michael</creatorcontrib><creatorcontrib>Januzzi, James L.</creatorcontrib><creatorcontrib>Lam, Carolyn S. P.</creatorcontrib><creatorcontrib>Lingvay, Ildiko</creatorcontrib><creatorcontrib>Pagidipati, Neha J.</creatorcontrib><creatorcontrib>Sattar, Naveed</creatorcontrib><creatorcontrib>Van Spall, Harriette G. C.</creatorcontrib><creatorcontrib>Verma, Subodh</creatorcontrib><creatorcontrib>McGuire, Darren K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current cardiology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Harrington, Josephine</au><au>Felker, G. Michael</au><au>Januzzi, James L.</au><au>Lam, Carolyn S. P.</au><au>Lingvay, Ildiko</au><au>Pagidipati, Neha J.</au><au>Sattar, Naveed</au><au>Van Spall, Harriette G. C.</au><au>Verma, Subodh</au><au>McGuire, Darren K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions</atitle><jtitle>Current cardiology reports</jtitle><stitle>Curr Cardiol Rep</stitle><addtitle>Curr Cardiol Rep</addtitle><date>2024-03-01</date><risdate>2024</risdate><volume>26</volume><issue>3</issue><spage>61</spage><epage>71</epage><pages>61-71</pages><issn>1523-3782</issn><eissn>1534-3170</eissn><abstract>Purpose of Review
Obesity is associated with cardiovascular (CV) conditions, including but not limited to atherosclerotic disease, heart failure, and atrial fibrillation. Despite this, the impact of intentional weight loss on CV outcomes for persons with obesity and established CV conditions remains poorly studied. New and emerging pharmacologic therapies for weight loss primarily targeting the incretin/nutrient sensing axes induce substantial and sustained weight loss. The glucagon-like-peptide 1 receptor agonists (GLP-1 RA) liraglutide and semaglutide have US FDA approval for the treatment of obesity, and the application for an obesity indication for the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide is presently under FDA review. Extensive phase II and IIIa randomized controlled trials are underway evaluating permutations of combined GLP-1 RA, GIP receptor agonist, GIP receptor antagonist, and glucagon receptor agonists. Clinical outcome trials of these therapies in persons with obesity at high risk of established CV conditions should make it possible to estimate the role of intentional weight loss in managing CV risk via these medications.
Recent Findings
High-dose once weekly injectable semaglutide (2.4 mg/week) use among persons with obesity and heart failure with preserved ejection fraction was effective at both reducing weight and improving health status; exercise capacity was also improved. Ongoing CV outcome trials of oral semaglutide and once weekly injectable tirzepatide will help to establish the role of these therapies among persons with other CV conditions. In addition to these two therapies targeting a CV claim or indication, many other new therapeutics for weight loss, as reviewed, are currently in development.
Summary
The impact of pharmacologic-induced weight loss on CV conditions for persons with obesity and established CV conditions is currently under investigation for multiple agents. These therapies may offer new avenues to manage CV risk in persons with obesity and with established or at high risk for CV disease.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>38551786</pmid><doi>10.1007/s11886-023-02016-z</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1523-3782 |
| ispartof | Current cardiology reports, 2024-03, Vol.26 (3), p.61-71 |
| issn | 1523-3782 1534-3170 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3022573838 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Atrial Fibrillation Cardiology Cardiometabolic Disease (DM and CV) (CJ Lavie Diabetes Mellitus, Type 2 Glucagon-Like Peptide 1 Heart Diseases Heart Failure Humans Hypoglycemic Agents Medicine Medicine & Public Health Obesity - complications Obesity - drug therapy Section Editor Topical Collection on Cardiometabolic Disease (DM and CV) Weight Loss |
| title | Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T22%3A36%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Worth%20Their%20Weight?%20An%20Update%20on%20New%20and%20Emerging%20Pharmacologic%20Agents%20for%20Obesity%20and%20Their%20Potential%20Role%20for%20Persons%20with%20Cardiac%20Conditions&rft.jtitle=Current%20cardiology%20reports&rft.au=Harrington,%20Josephine&rft.date=2024-03-01&rft.volume=26&rft.issue=3&rft.spage=61&rft.epage=71&rft.pages=61-71&rft.issn=1523-3782&rft.eissn=1534-3170&rft_id=info:doi/10.1007/s11886-023-02016-z&rft_dat=%3Cproquest_cross%3E3022573838%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3022573838&rft_id=info:pmid/38551786&rfr_iscdi=true |